New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLeuprolide vs PT-141 (Bremelanotide)

Leuprolide vs PT-141 (Bremelanotide)

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Leuprolide
Sexual Health & Libido
PT-141 (Bremelanotide)
Summary
Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
Half-Life
~3 hours (SC/IM), but depot formulations last 1–12 months
2–3 hours
Admin Route
SubQ, IM
SubQ
Research
Typical Dose
7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
0.5–1.75 mg
Frequency
Per depot schedule
As needed (not daily)
Key Benefits
  • Medical: reduces testosterone in prostate cancer
  • Medical: suppresses estrogen in endometriosis and uterine fibroids
  • Medical: delays precocious puberty
  • Research: testosterone rebound effect after short course
  • Transgender care: hormone suppression in adolescents
  • Research: hormonal re-sensitization protocols
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
Side Effects
  • Hot flashes (with testosterone suppression)
  • Decreased libido and erectile dysfunction
  • Initial testosterone flare (first 1–2 weeks)
  • Bone density loss with long-term use
  • +3 more
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
Stacks With